Plasma Soluble (Pro)renin Receptor Reflects Renal Damage

Naro Ohashi¹*, Shinsuke Isobe¹, Sayaka Ishigaki¹, Takahisa Suzuki², Takamasa Iwakura¹, Masafumi Ono³, Tomoyuki Fujikura¹, Takayuki Tsuji¹, Atsushi Otsuka², Yasuo Ishii², Hiroshi Furuse², Akihiko Kato³, Seiichiro Ozono², Hideo Yasuda¹

¹ Internal Medicine 1, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431–3192, Japan, 2 Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431–3192, Japan, 3 Blood Purification Unit, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431–3192, Japan

* ohashi-n@hama-med.ac.jp

Abstract

Background
(Pro)renin receptor [(P)RR], a specific receptor for renin and prorenin, was identified as a member of the renin-angiotensin system (RAS). (P)RR is cleaved by furin, and soluble (P)RR [s(P)RR] is secreted into the extracellular space. Previous reports have indicated that plasma s(P)RR levels show a significant positive relationship with urinary protein levels, which represent renal damage. However, it is not fully known whether plasma s(P)RR reflects renal damage.

Methods
We recruited 25 patients who were admitted to our hospital to undergo heminephrectomy. Plasma s(P)RR levels were examined from blood samples drawn before nephrectomy. The extent of renal damage was evaluated by the levels of tubulointerstitial fibrosis. Immunohistochemical analysis of intrarenal (P)RR and cell surface markers (cluster of differentiation [CD]3, CD19, and CD68) was performed on samples taken from the removed kidney. Moreover, double staining of (P)RR and cell surface markers was also performed.

Results
There were significant positive relationships between plasma s(P)RR and tubulointerstitial fibrosis in all the patients and those not receiving RAS blocker therapy. Significant positive relationships were found between plasma s(P)RR levels and the extent of tubulointerstitial fibrosis after adjustment for age, sex, body weight, blood pressure, and plasma angiotensin II, in all the patients and those not receiving RAS blockers. Moreover, (P)RR expression was elevated in infiltrated mononuclear cells but not connecting tubules or collecting ducts and vessels. Infiltrated cells positive for (P)RR consisted of CD3 and CD68 but not CD19.
Conclusions

These data suggest that plasma s(P)RR levels may reflect (P)RR expression levels in infiltrated mononuclear cells, which can be a surrogate marker of renal damage.

Introduction

(Pro)renin receptor [(P)RR] is a specific receptor for renin and prorenin and has been identified as a component of the renin-angiotensin system (RAS) by Nguyen et al. in 2002 [1]. (P)RR is a 350-amino acid protein with a single transmembrane domain and is widely expressed in various tissues, including the kidney, heart, liver, placenta, and pancreas. (P)RR is especially expressed in various regions of the kidney, including glomeruli (mesangial cells and podocytes), proximal and distal tubules, collecting ducts, and vessels [1–3].

When prorenin binds to (P)RR, multifunctions are fulfilled. First, prorenin undergoes a conformational change, without proteolytic cleavage, to develop renin activity. This process plays a role in tissue RAS regulation. Second, (P)RR activation triggers the mitogen-activated protein kinases and extracellular signal-regulated kinase 1/2 phosphorylation, which in turn upregulates the expression of profibrotic genes such as transforming growth factor-β 1, plasminogen activator inhibitor type 1, collagens, and fibronectin. In addition, (P)RR functions as an accessory protein of vacuolar proton adenosine triphosphatase (V-ATPase) and is involved in the control of intracellular and extracellular pH. Finally, (P)RR is associated with Wnt-β-catenin signaling pathways, which are essential for adult and embryonic stem cell biology, embryonic development, and diseases such as cancer [4, 5].

Cleavage of PRR by furin yields soluble (P)RR [s(P)RR]. Thereafter, s(P)RR is secreted into the extracellular space and is ultimately found in blood and urine [3, 6]. Because s(P)RR also binds to prorenin and mediates the activation of prorenin, it is possible that s(P)RR also has physiological functions [3].

The importance of s(P)RR has been indicated in clinical studies. Watanabe et al. demonstrated that high circulating levels of s(P)RR during early pregnancy predict a subsequent elevation in blood pressure (BP), and high concentrations at delivery were associated with preeclampsia [7]. Moreover, in patients with chronic kidney disease (CKD), Hamada et al. recruited 374 patients whose mean serum creatinine (sCr) levels were 1.9 ± 1.6 mg/dL. In their study, they demonstrated that s(P)RR levels were positively associated with levels of urinary protein/urinary Cr. In addition, they indicated that the baseline levels of s(P)RR were positively associated with the annual change of sCr, and that those were negatively associated with the annual change of estimated glomerular filtration rate (eGFR) [8]. However, there was no direct evidence as to whether plasma s(P)RR levels were associated with renal damage. Therefore, this study was performed to clarify the relationships among plasma s(P)RR and renal damage using kidney samples that were obtained by nephrectomy.

Materials and Methods

Recruitment of patients

This study was approved by the ethics committee of Hamamatsu University School of Medicine (No. 25–92) and was conducted in accordance with the guidelines of the Declaration of Helsinki. All the patients provided written informed consent. We recruited 25 patients (age range, 20–80 years) who were admitted to our hospital to undergo heminephrectomy between
September 2013 and July 2015, regardless of the range of renal function and antihypertensive medication. The causes of nephrectomy were the following: renal cell carcinoma, 22; ureteral carcinoma, 2; and kidney metastasis, 1.

### Study protocols

In patients on hemodialysis (HD), vital signs, such as height, dry weight, systolic and diastolic BPs, and heart rate, were measured on the day before surgery. The HD session was performed after the measurements. Blood samples were drawn just before the HD session. Both patients on peritoneal dialysis and not on dialysis also underwent the aforementioned procedures preoperatively. The procedures were performed 0.88 ± 0.99 days before nephrectomy.

The patients were asked to rest in the supine position for at least 15 min before blood sample collection at 9 AM. Thereafter, blood samples were centrifuged at 3000 rpm for 10 min at 4°C and stored at −80°C until further assay as per a previous report [9]. Kidney samples were collected immediately after nephrectomy and prepared as described in the subsequent sections.

### Measurement of renal function and plasma renin activity (PRA), plasma angiotensin II (AngII) and plasma s(P)RR

The sCr concentrations were measured in the clinical laboratory of the study hospital.

The eGFR was calculated using the Japanese eGFR equation [10]. PRA and plasma AngII levels were determined by radioimmunoassay (RIA) (SRL, Tokyo, Japan) and plasma s(P)RR level were measured by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instruction (IBL, Takasaki, Japan).

### Evaluation of tubulointerstitial lesions

A small part of the resected kidney was fixed in formalin and embedded in paraffin. Tissue sections (3 μm) were stained with Masson’s trichrome for histopathological evaluation of tubulointerstitial lesions. Because the extent of tubulointerstitial fibrosis reflects the severity of renal damage [11], the percentages of tubulointerstitial fibrosis were evaluated in microscopic fields observed at ×100 magnification. Ten microscopic fields were evaluated for each patient using a point-counting method, and mean values were calculated. All quantitative analyses were performed in a blind manner to avoid bias.

### Immunohistochemical analysis of intrarenal (P)RR

To evaluate the intrarenal (P)RR expression regions and levels, immunostaining for (P)RR in kidney sections was performed using the EnVision™ + Dual Link System-HRP (Dakocytonation, Glostrup, Denmark), as previously described [11–14]. The primary antibody was rabbit anti-(P)RR antibody, which detected within residues 300 to the C-terminus (Abcam, Tokyo, Japan). Sections incubated without the primary antibody were used as controls. To examine the expression levels of (P)RR, 10 small vessels and collecting ducts or connecting tubular cells and infiltrated cells in 10 microscopic fields at ×100 magnification were evaluated for representative samples according to the stained levels for (P)RR: unstained, 0; weak, 1; moderate, 2; and severe, 3, and mean values were calculated.

### Immunohistochemical analysis of infiltrated cells using cell surface markers in serial sections

Infiltrated cells were stained by using cell surface markers to determine what kinds of cells were infiltrated. CD3-, CD19-, or CD68-positive cells indicate T cell, B cell, and monocyte/
macrophage lines, respectively. The primary antibody for CD3 was mouse monoclonal from Novoceastra/Leica Biosystems, Heiderberg, Germany, and those for CD19 and CD68 were mouse monoclonal from Dakocytomation. The patient with eGFR of 27 mL/min/1.73m² was selected for immunohistochemical analyses because remarkable infiltrated cells were present in the tissue section.

**Double staining by immunofluorescence**

Double staining of paraffin sections was performed using anti-(P)RR antibody with either anti-CD3, anti-CD19, or anti-CD68 antibody. The sections were incubated with Alexa Fluor 546- and 488-labeled secondary antibodies (Molecular Probes, Eugene, OR, USA) for the anti-(P)RR and cell surface marker antibodies, respectively. The patient whose eGFR was 27 mL/min/1.73m² was selected for the immunofluorescence analyses. Localization of (P)RR and cell surface markers was investigated with an immunofluorescence microscope (BX50, Olympus, Tokyo, Japan).

**Statistical analysis**

Results were expressed as the mean ± standard deviation. Dry weight was used as body weight for analyses in patients on HD. All parameters, except for PRA, showed a normal distribution. On the other hand, because PRA did not show a normal distribution, logarithmic transformation was applied. The correlations between plasma s(P)RR and other parameters were evaluated by using Pearson’s product-moment correlation coefficient. Multiple linear regression analyses for plasma s(P)RR levels were adjusted for age, sex, body weight, systolic BP, plasma AngII, and the extent of interstitial fibrosis. Age, sex, and body weight were selected as variables because these parameters are common in performing multiple linear regression analyses. In addition, systolic BP and plasma AngII, component of circulating RAS, were also adjusted as they are associated with renal damage. We considered p < 0.05 statistically significant. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) software version 20 (SPSS Inc., Chicago, Illinois, USA).

**Results**

**Characteristics of all the patients**

The patient characteristics are listed in Table 1. Dialysis was performed for all the patients with an eGFR < 15 mL/min/1.73m²; 8 patients required HD and 1 required PD. The extent of tubulointerstitial damage was proportional to the extent of renal dysfunction (Fig 1).

**Relationships between plasma s(P)RR levels and other parameters in all the patients**

We evaluated the correlation between plasma s(P)RR and other parameters in all the patients. Plasma s(P)RR levels were not correlated with age, height, body weight, body mass index (BMI), BPs, heart rate, PRA, and plasma AngII. However, significant positive relationship was found between plasma s(P)RR levels and the extent of interstitial fibrosis (Table 2).

**Multiple linear regression analyses for plasma s(P)RR levels in all the patients**

To evaluate the relationship between plasma s(P)RR levels and the extent of interstitial fibrosis, hence the contribution of s(P)RR to tubulointerstitial damage, we performed multiple linear
regression analyses, after adjusting for age, sex, body weight, systolic BP, and plasma AngII levels (Table 3). We selected age, sex, and body weight as variables, because these parameters are common in performing multiple linear regression analyses. In addition, systolic BP and plasma AngII were also adjusted for, as they are associated with renal damage. All multiple regression equations revealed high prediction accuracy and significance. The analyses revealed that plasma s(P)RR was associated with the levels of interstitial fibrosis when age, sex, body weight, systolic BP, and plasma AngII were adjusted as independent variables.

**Characteristics of patients not on RAS blocker therapy**

Because RAS blockers influence both systemic and intrarenal RAS expression levels [12, 15, 16], we excluded 7 patients who were prescribed RAS blockers (i.e., angiotensin II receptor

---

**Table 1. Characteristics of all the patients.**

| Characteristic          | Value                          |
|-------------------------|--------------------------------|
| Age, year               | 62.9 ± 15.0                    |
| Sex                     | Male: 19, Female: 6            |
| Causes of nephrectomy   | Renal cell carcinoma: 22       |
|                         | Ureteral carcinoma: 2          |
|                         | Metastasis in kidney: 1        |
| Past history            | Heart disease: 1               |
|                         | Malignancy: 3                  |
|                         | Others: 15                     |
| Comorbidity             | Heart disease: 6               |
|                         | Cerebrovascular disease: 1     |
|                         | Malignancy: 1                  |
|                         | Hypertension: 10               |
|                         | Diabetes mellitus: 7           |
|                         | Others: 15                     |
| eGFR (ml/min/1.73m²)    | eGFR > 90: 3                   |
|                         | 60 ≤ eGFR < 90: 6              |
|                         | 30 ≤ eGFR < 60: 6              |
|                         | 15 ≤ eGFR < 30: 1              |
|                         | eGFR < 15: 9                   |
| Use of antihypertensives| RAS blockers: 7                |
|                         | Diuretics: 2                   |
|                         | Others: 7                      |
| Height (m)              | 164.3±8.7                      |
| Body weight (kg)        | 61.6±12.7                      |
| BMI (kg/m²)             | 23.2±3.8                       |
| Systolic BP (mmHg)      | 135.6±20.0                     |
| Diastolic BP (mmHg)     | 78.8±11.3                      |
| Heart rate (/min)       | 72.7±13.4                      |
| PRA (ng/ml/hr)          | -0.011±0.33                    |
| Plasma AngII (pg/ml)    | 15.9±11.4                      |
| Plasma s(P)RR (ng/ml)   | 24.36±7.13                     |
| Interstitial fibrosis (%)| 48.9±39.8                     |

Abbreviations: eGFR, estimated glomerular filtration rate; BMI, body mass index; BP, blood pressure; PRA, plasma renin activity; AngII, angiotensin II; s(P)RR, soluble (pro)renin receptor.

doi:10.1371/journal.pone.0156165.001
blockers, angiotensin-converting enzyme inhibitors, mineralocorticoid receptor blockers, or direct renin inhibitors), and their characteristics are listed in S1 Table. Of the 5 patients, those with an eGFR < 15 mL/min/1.73m² underwent dialysis (HD, 4; PD, 1).
We evaluated the correlation between plasma s(P)RR and other parameters in the patients not on RAS blocker therapy. Plasma s(P)RR levels were not correlated with age, height, BP, heart rate, and circulating RAS. However, we found significant positive relationships between plasma s(P)RR and body weight, BMI or the extent of interstitial fibrosis (S2 Table).

Multiple linear regression analyses for plasma s(P)RR levels for patients not on RAS blockers

We performed multiple linear regression analyses to assess the correlation between s(P)RR levels and extent of interstitial fibrosis and to evaluate the contribution of s(P)RR toward tubulointerstitial damage, for patients not on RSA blockers (S3 Table). All multiple regression equations revealed high prediction accuracy and significance. The analyses revealed an association between plasma s(P)RR and the extent of interstitial fibrosis similar to that found in all the patients.

Table 2. Correlations between plasma soluble (pro)renin receptor [s(P)RR] and clinical parameters in all the patients.

| Parameter          | Correlation coefficient | p value |
|--------------------|-------------------------|---------|
| Age (year)         | 0.039                   | 0.85    |
| Height (m)         | 0.093                   | 0.66    |
| Body weight (kg)   | 0.33                    | 0.11    |
| BMI (kg/m²)        | 0.35                    | 0.093   |
| Systolic BP (mmHg) | 0.16                    | 0.46    |
| Diastolic BP (mmHg)| 0.092                   | 0.66    |
| Heart rate (/min)  | -0.19                   | 0.37    |
| PRA (ng/ml/h)      | 0.18                    | 0.41    |
| Plasma AngII (pg/ml)| 0.39                  | 0.056   |
| Interstitial fibrosis (%) | 0.52           | 0.008   |

Abbreviations: BMI, body mass index; BP, blood pressure; PRA, plasma renin activity; AngII, angiotensin II.

doi:10.1371/journal.pone.0156165.t002

Table 3. Multiple regression analyses for plasma soluble (pro)renin receptor [s(P)RR] in all the patients.

| Parameter          | Model 1       | Model 2       | Model 3       |
|--------------------|---------------|---------------|---------------|
|                    | R = 0.62      | p = 0.049     | R = 0.71      | p = 0.019     | R = 0.76      | p = 0.011     |
| Age (year)         | 0.057         | 0.78          | 0.16          | 0.40          | 0.18          | 0.33          |
| Sex                | 0.15          | 0.46          | 0.16          | 0.39          | 0.21          | 0.24          |
| Body weight (kg)   | 0.38          | 0.079         | 0.48          | 0.024         | 0.51          | 0.013         |
| Systolic BP (mmHg) | -0.50         | 0.049         | -0.38         | 0.13          |               |               |
| Plasma AngII (pg/ml)| 0.51        | 0.012         | 0.83          | 0.002         | 0.71          | 0.006         |
| Interstitial fibrosis (%) | 0.31       | 0.086         | 0.31          | 0.086         | 0.31          | 0.086         |

BP, blood pressure; AngII, angiotensin II.

doi:10.1371/journal.pone.0156165.t003
Intrarenal (P)RR protein expression regions and levels

Immunostaining for (P)RR was observed to clarify the expression regions and levels. The levels of immunostaining were weaker in the collecting ducts or connecting tubular cells of the patients who had worse renal function, including patients on dialysis, than those with better renal function. Immunostaining results for small vessels did not significantly differ among the patients. However, mononuclear cell infiltration was prominent in patients with poor renal function, such as those on dialysis, compared with those with better renal function, and some of the infiltrated cells were positive for (P)RR (Fig 2).

Staining of infiltrated cells by using (P)RR and cell surface markers in serial sections and double staining of (P)RR and cell surface markers

Staining of infiltrated cells using (P)RR and cell surface markers in serial sections and double staining of (P)RR and cell surface markers were performed to determine what kinds of cells were infiltrated. Most of the infiltrated cells positive for (P)RR were CD3-positive cells (T cell line), and (P)RR and CD3 were merged well. CD19-positive cells (B cell line) were sparse in infiltrated cells, and it was difficult to determine the merged cells clearly. CD68-positive cells (monocyte/macrophage cell line) were diffusely scattered, and a few merged cells were found in the immunofluorescence study (Figs 3 and 4).

Discussion

In this study, significant positive relationships were found between plasma s(P)RR levels and levels of tubulointerstitial fibrosis in both all the patients and the patients without RAS blockers. These relationships were maintained even after adjustment for age, sex, body weight, plasma AngII levels, a surrogate marker of circulating RAS, and systolic BP in all the patients and the patients without RAS blockers. These data suggest that plasma s(P)RR can be a surrogate marker for renal damage.

It is not clear why plasma s(P)RR reflects renal damage in this study. A previous report demonstrated increased expression levels of (P)RR in the remnant kidneys of 5/6 nephrectomized rats [17]. Ichihara et al. provided direct evidence that (P)RR blockers could significantly prevent and suppress end-stage kidney disease [18]. In addition, renal damage upregulates renal RAS activity, and subsequently, increases renal AngII. Increased renal AngII stimulates inflammation and fibrosis in the renal interstitial region due to enhanced oxidative stress through an increase in NADPH oxidase activity [19] and elevation of transforming growth factor-β1 expression levels [20]. Moreover, increased renal AngII induces interstitial macrophage infiltration due to augmentation of monocyte chemotactic protein-1 [21]. Most infiltrated cells are positive for (P)RR as indicated in this study, and s(P)RR is cleaved from (P)RR in the cells and is secreted and ultimately found in the blood. In this way, it is possible that s(P)RR is the surrogate marker of intrarenal fibrosis.

Three components (small vessels, collecting ducts or connecting tubules, and infiltrated cells) were positive for (P)RR in this study. Immunostaining results for small vessels did not significantly differ among the patients, and the levels of immunostaining were weaker in the collecting ducts and connecting tubular cells of the patients who had worse renal function than those with better renal function in this study. Recently, it has been shown that (P)RR is expressed in human lymphocytes and monocytes and that (P)RR contributes to inflammation [22]. Because we did not separate peripheral blood mononuclear cells and analyze the expression levels of (P)RR using polymerase chain reaction or immunoblotting, we could not quantify (P)RR expression levels in the infiltrated cells precisely. However, more infiltrated cells were
Fig 2. Immunostaining for (pro)renin receptor [(P)RR]. Ten small vessels and collecting ducts or connecting tubular cells and infiltrated cells in 10 microscopic fields at ×100 magnification were evaluated for representative samples according to the stained levels for (P)RR: unstained, 0; weak, 1; moderate, 2; and severe, 3; and mean values were calculated. There were no significant differences among patients in the levels of immunostaining in the small vessels. The levels of immunostaining in the collecting ducts or connecting tubular cells for the patients who had worse renal function were weaker than those who had better renal function. On the other hand, more infiltrated cells for (P)RR positive were found for patients who had the worse renal function, compared with those who had better renal function. Sharps (#), asterisks (*), and arrows (→) indicate the vessels, the collecting ducts or connecting tubule, and infiltrating cells positive for (P)RR, respectively. Numbers below each figure mean estimated glomerular filtration rate of each patient. Original magnification ×200. The scale bar in each figure represents 100 μm. The same patients in whom
found, and some of the infiltrated cells were positive for (P)RR more frequently according to the renal dysfunction. In addition, we determined that most of the infiltrated cells positive for (P)RR were CD3-positive (T cell line), and some of them were CD68-positive cells (monocyte/macrophage cell line), and CD19-positive cells (B cell line) were not evident. These results may suggest that plasma s(P)RR was supplied from the infiltrated (P)RR-positive T cells or monocytes/macrophages that coincide with the previous report [22]. However, s(P)RR levels are affected by many factors, including RAS blocker administration [23], lipid metabolites such as high-density lipoprotein cholesterol and triglycerides [24], age [24], and obstructive sleep apnea syndrome [25]. Moreover, the correlation between s(P)RR level and furin activity has not yet been investigated. Further investigations are expected to determine the mechanism of s(P)RR generation and the contribution of s(P)RR for renal damage.

The significant positive relationships between plasma s(P)RR levels and renal damage were obtained in all the patients in this study. Because previous reports showed that angiotensin receptor blockers significantly inhibit renal expression of (P)RR mRNA and protein in diabetic rats and patients with CKD [8, 26], we reanalyzed the relationship between plasma s(P)RR levels and renal damage, using only the patients without RAS treatment, and the significant positive relationships between plasma s(P)RR levels and renal damage were also obtained in the patients without RAS treatment similar to all the patients. These results strongly indicate the importance of plasma s(P)RR for renal damage.

Masson’s trichrome staining were performed were selected. Black, dotted, and diagonal bars indicate the immunostaining intensity levels of small vessels, collecting ducts or connecting tubular cells, and infiltrated cells, respectively. Abbreviations: PD, peritoneal dialysis; HD, hemodialysis

doi:10.1371/journal.pone.0156165.g002

Fig 3. Staining of infiltrated cells by using (pro)renin receptor ((P)RR) and cell surface markers in serial sections. (P)RR was positive for vessels, collecting ducts or connecting tubules, and infiltrated cells. Most of infiltrated cells positive for (P)RR were CD3-positive cells (T cell line), and CD19-positive cells (B cell line) were sparse. CD68 positive cells (monocyte/macrophage line) were diffusely scattered. Original magnification x200. The scale bar in each figure represents 100 μm. The patient whose eGFR was 27 mL/min/1.73m² was selected for the immunohistochemical analyses because remarkable infiltrated cells were present in the tissue section.

doi:10.1371/journal.pone.0156165.g003
Significant positive relationship between sCr levels and s(P)RR levels and significant negative relationship between eGFR levels and s(P)RR levels have been previously reported [8, 24]. It is likely that the relationship between s(P)RR and tubulointerstitial fibrosis levels was influenced by renal function in this study. However, the purpose of this study was to clarify that plasma s(P)RR levels reflected renal damage for all the patients, including patients on dialysis.

Fig 4. Double staining by immunofluorescence using anti-(P)RR antibody and antibodies for cell surface markers. Double staining of paraffin sections was performed using anti-(P)RR antibody with either anti-CD3, anti-CD19, or anti-CD68 antibody, respectively. (P)RR and CD3 were merged well. A few merged cells of (P)RR and CD68 were found in the immunofluorescence study. On the other hand, it was difficult to determine the merged cells of (P)RR and CD19 clearly. Original magnification ×400. The scale bar in each figure represents 100 μm. The patient whose eGFR was 27 mL/min/1.73m² was selected for the immunofluorescence analyses.

doi:10.1371/journal.pone.0156165.g004
Adjustment for renal function was not performed in this study because eGFR was not applicable to patients on dialysis.

We have investigated the relationship between urinary albumin and protein excretion that is a surrogate marker of renal damage and s(P)RR. Contrary to expectations, no significant relationships were found between them ($r = 0.088$, $p = 0.76$). The following are the possible causes: (1) eight hemodialysis patients were excluded because of anuria, and the sample size became much smaller. (2) The urinary protein excretion levels that could be measured from the remaining patients were $237.8 \pm 307.6$ mg/day, and it is supposed that the causes of renal damage in these patients were not glomerulopathies with proteinuria.

Because (P)RR is widely expressed in various tissues, including the kidney, heart, liver, placenta, and pancreas, it is possible that increased s(P)RR came from other tissues but not the kidney. However, no tissue is injured in other tissues. Therefore, it is less likely that infiltrated cells positive for (P)RR came from other tissues. However, to clarify the origin of s(P)RR, the relationship between tissue-specific (P)RR expression levels and expression levels in the kidney is needed to be investigated using tissue-specific (P)RR knockout mouse. In the future, we would like to perform these experiments.

In summary, significant positive relationships were found between plasma s(P)RR levels and levels of tubulointerstitial fibrosis in both all the patients and the patients without RAS blocker therapy. These relationships were maintained even after adjustment for age, sex, body weight, plasma AngII, and systolic BP. In addition, (P)RR expression was elevated in infiltrated mononuclear cells but not in connecting tubules or collecting ducts and vessels. These data suggest that plasma s(P)RR that may reflect (P)RR expression levels in infiltrated mononuclear cells can be a surrogate marker for renal damage.

Supporting Information

S1 Table. Characteristics of patients without renin-angiotensin system (RAS) blockers.

S2 Table. Correlations between plasma soluble (pro)renin receptor [s(P)RR] and clinical parameters in patients without renin-angiotensin system (RAS) blockers.

S3 Table. Multiple regression analyses for plasma soluble (pro)renin receptor [s(P)RR] in patients without renin-angiotensin system (RAS) blockers.

Acknowledgments

The authors acknowledge Daisuke Motoyama, Takayuki Sugiyama, and Masao Nagata (Urology, Hamamatsu University School of Medicine) for performing heminephrectomy and providing adequate kidney samples to us. Moreover, the authors acknowledge Satoshi Baba (Pathology, Hamamatsu University School of Medicine) for providing antibodies for cell surface markers and adequate condition to stain the samples for us.

Author Contributions

Conceived and designed the experiments: NO S. Isobe S. Ishigaki. Performed the experiments: NO TS TI MO TF TT AO YI HF. Analyzed the data: NO S. Isobe S. Ishigaki. Contributed reagents/materials/analysis tools: NO S. Isobe S. Ishigaki. Wrote the paper: NO HY. Reviewed and rewrote the manuscript adequately: AK SO.
References

1. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002; 109: 1417–1427. PMID: 12045255

2. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burcklé CA, et al. Prorenin is the endogenous agonist of the (pro)renin receptor.Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens. 2007; 25: 2441–2453. PMID: 17984666

3. Gonzalez AA, Lara LS, Luffman C, Seth DM, Prieto MC. Soluble form of the (pro)renin receptor is augmented in the collecting duct and urine of chronic angiotensin II-dependent hypertensive rats. Hypertension. 2011: 57: 859–864. doi: 10.1161/HYPTENSIONNAH.110.167957 PMID: 21321306

4. Nguyen G. Renin and prorenin receptor in hypertension: what’s new? Curr Hypertens Rep 2011: 13: 79–85. doi: 10.1007/s11906-010-0172-9 PMID: 21125352

5. Oshima Y, Morimoto S, Ichihara A. Roles of the (pro)renin receptor in the kidney. World J Nephrol. 2014: 6:302–307.

6. Cousin C, Bracquart D, Contrepas A, Corvol P, Muller L, Nguyen G. Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension. 2009: 53: 1077–1082. doi: 10.1161/HYPTENSIONNAH.108.127238 PMID: 19389613

7. Watanabe N, Bokuda K, Fujiwara T, Suzuki T, Milo A, Morimoto S, et al. Soluble (pro)renin receptor and blood pressure during pregnancy: a prospective cohort study. Hypertension. 2012: 60: 1250–1256. doi: 10.1161/HYPTENSIONNAH.112.197418 PMID: 23045437

8. Hamada K, Taniguchi Y, Shimamura Y, Inoue K, Ogata K, Ishihara M, et al. Serum level of soluble (pro)renin receptor is modulated in chronic kidney disease. Clin Exp Nephrol. 2013: 17: 846–855. doi: 10.1007/s10157-013-0803-y PMID: 23564382

9. Isobe S, Ohashi N, Fujikura T, Tsuji T, Sakao Y, Yasuda H, et al. Disturbed circadian rhythm of the intrarenal renin-angiotensin system: relevant to nocturnal hypertension and renal damage. Clin Exp Nephrol. 2015 19: 231–239. doi: 10.1007/s10157-014-0973-2 PMID: 24728489

10. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009: 53: 982–992. doi: 10.1053/j.ajkd.2008.12.034 PMID: 19339088

11. Huang Y, Yamamoto T, Misaki T, Suzuki T, Milo A, Morimoto S, et al. Enhanced intrarenal receptor-mediated prorenin activation in chronic progressive anti-thymocyte serum nephritis rats on high salt intake. Am J Physiol Renal Physiol. 2012: 303: F130–138. doi: 10.1152/ajprenal.00058.2008 PMID: 22496409

12. Ohashi N, Yamamoto T, Huang Y, Misaki T, Fukasawa H, Suzuki H, et al. Intrarenal RAS activity and urinary angiotensinogen excretion in anti-thymocyte serum nephritis rats. Am J Physiol Renal Physiol. 2008: 295: F1512–1518. doi: 10.1152/ajprenal.00058.2008 PMID: 18784264

13. Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, Urushihara M, et al. Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice. Clin Exp Pharmacol Physiol. 2009: 36: 750–755. doi: 10.1111/j.1440-1681.2009.05172.x PMID: 19298532

14. Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, Urushihara M, et al. Activation of reactive oxygen species and the renin-angiotensin system in IgA nephropathy model mice. Clin Exp Pharmacol Physiol. 2009: 36: 509–515. doi: 10.1111/j.1440-1681.2008.05107.x PMID: 19673933

15. Kobori H, Ozawa Y, Suzuki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol. 2005 16: 2073–2080. PMID: 15888567

16. Kobori H, Alper AB Jr, Shenava R, Katsurada A, Saito T, Ohashi N, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension. 2009: 53: 344–350. doi: 10.1161/HYPTENSIONNAH.108.123802 PMID: 19075095

17. Hirose T, Mori N, Totsune K, Morimoto R, Maejima T, Kawamura T, et al. Increased expression of (pro)renin receptor in the remnant kidneys of 5/6 nephrectomized rats. Regul Pept. 2010: 8: 93–99.

18. Ichihara A, Itoh H, Inagami T. Critical roles of (pro)renin receptor-bound prorenin in diabetes and hypertension: sallies into therapeutic approach. J Am Soc Hypertens. 2008 2: 15–19. doi: 10.1016/j.jash.2007.08.001 PMID: 20409880

19. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension. 2003: 42: 206–212. PMID: 12847113

20. Macconi D, Remuzzi G, Benigni A. Key fibrogenic mediators: old players. Renin-angiotensin system. Kidney Int Suppl (2011). 2014: 4:58–64.
21. Ozawa Y, Kobori H, Suzaki Y, Navar LG. Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol. 2007: 292: F330–339. PMID: 16804106

22. Narumi K, Hirose T, Sato E, Mori T, Kisu K, Ishikawa M, et al. A functional (pro)renin receptor is expressed in human lymphocytes and monocytes. Am J Physiol Renal Physiol. 2015: 308: F487–499. doi: 10.1152/ajprenal.00206.2014 PMID: 25503726

23. Nguyen G, Blanchard A, Curis E, Bergerot D, Chambron Y, Hirose T, et al. Plasma soluble (pro)renin receptor is independent of plasma renin, prorenin, and aldosterone concentrations but is affected by ethnicity. Hypertension. 2014: 63: 297–302. doi: 10.1161/HYPERTENSIONAHA.113.02217 PMID: 24218434

24. Morimoto S, Ando T, Niiyama M, Seki Y, Yoshida N, Watanabe D, et al. Serum soluble (pro)renin receptor levels in patients with essential hypertension. Hypertens Res. 2014: 37: 642–648. doi: 10.1038/hr.2014.46 PMID: 24646643

25. Nishijima T, Tajima K, Takahashi K, Sakurai S. Elevated plasma levels of soluble (pro)renin receptor in patients with obstructive sleep apnea syndrome: association with polysomnographic parameters. Peptides. 2014: 56: 14–21. doi: 10.1016/j.peptides.2014.03.008 PMID: 24657284

26. Siragy HM, Huang J. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp Physiol. 2008: 93: 709–714. doi: 10.1113/ expphysiol.2007.040550 PMID: 18192338